$AUPH News

Tang Capital Raises Aurinia Pharmaceuticals Holding to 10%

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Affirms FY2026 Sales Guidance of $315.000M-$325.000M vs $326.190M Est

Aurinia Pharmaceuticals Q1 EPS $0.25 Beats $0.19 Estimate, Sales $77.705M Beat $77.390M Estimate

AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) Screens Strong on Minervini Trend Template and High Growth Momentum

ARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock?

Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

Does Aurinia’s Tang‑Led Leadership Overhaul Reshape the Bull Case for Aurinia Pharmaceuticals (AUPH)?

Aurinia Pharmaceuticals: New Management, Continued Lupkynis Performance

AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH): A High-Growth Momentum and Technical Trend Case Study

MKT Capital Applauds Aurinia Pharmaceuticals’ Management Transition

Aurinia Announces Management Transition

Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning

Aurinia Pharmaceuticals Appoints Kevin Tang To Succeed Peter Greenleaf As CEO; Names Ryan Cole COO And Michael Hearne CFO

Aurinia Pharmaceuticals Appoints Kevin Tang To Succeed Peter Greenleaf As CEO; Names Ryan Cole COO And Michael Hearne CFO

Evommune Stock Sees RS Rating Rise To 91

Is Aurinia Pharmaceuticals (AUPH) Pricing Reflect Long Term Value After 71% One Year Gain

KalVista Pharmaceuticals Stock Sees RS Rating Jump To 86

Aurinia Pharmaceuticals: Waiting For Another Opportunity (Downgrade)

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Passes Key Growth Screener from "The Little Book That Makes You Rich"